FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2734672213> ?p ?o ?g. }

• W2734672213 endingPage "982" @default.
• W2734672213 startingPage "971" @default.
• W2734672213 abstract "Recent developments in several fields, including somatic cell reprogramming and precise gene editing, are leading to novel cell-based therapies. Inherent heterogeneities in cell populations and methods for cell extraction, culture, and processing produce cell therapy products with considerable interbatch and intrabatch variability, hampering clinical translation and adoption of therapies. Standards and critical quality attributes need to be developed and verified to have clear benchmarks for the development of cell therapy products. Biomaterials could be engineered to reduce the root causes of heterogeneity, enhance functionality of cell-based therapies, and develop new standards for manufacturing. Emerging manufacturing processes to generate regenerative advanced therapies can involve extensive genomic and/or epigenomic manipulation of autologous or allogeneic cells. These cell engineering processes need to be carefully controlled and standardized to maximize safety and efficacy in clinical trials. Engineered biomaterials with smart and tunable properties offer an intriguing tool to provide or deliver cues to retain stemness, direct differentiation, promote reprogramming, manipulate the genome, or select functional phenotypes. This review discusses the use of engineered biomaterials to control human cell manufacturing. Future work exploiting engineered biomaterials has the potential to generate manufacturing processes that produce standardized cells with well-defined critical quality attributes appropriate for clinical testing. Emerging manufacturing processes to generate regenerative advanced therapies can involve extensive genomic and/or epigenomic manipulation of autologous or allogeneic cells. These cell engineering processes need to be carefully controlled and standardized to maximize safety and efficacy in clinical trials. Engineered biomaterials with smart and tunable properties offer an intriguing tool to provide or deliver cues to retain stemness, direct differentiation, promote reprogramming, manipulate the genome, or select functional phenotypes. This review discusses the use of engineered biomaterials to control human cell manufacturing. Future work exploiting engineered biomaterials has the potential to generate manufacturing processes that produce standardized cells with well-defined critical quality attributes appropriate for clinical testing. cells or tissue obtained from an external donor. a tripeptide composed of the amino acids Arg–Gly–Asp (RGD), identified from fibronectin, that is known to facilitate cell binding through integrin receptors. cells or tissue obtained from the patient himself or herself. Autologous transplantation does not require an external donor and, as the body recognizes the cells, helps avoids rejection. the use of living biological systems or their products to generate materials, devices, and biological products in a scalable, industrial manner. natural or synthetic materials with biological activity or functionality. autologous or allogenic living cells used within the body for therapeutic benefit. a type of immunotherapy where T cells are genetically modified with a synthetic receptor, which binds to tumors and potentiates a cytotoxic response within the T cell. T cells could be harvested directly from the patient in an autologous manner or be derived from allogeneic sources. physical, chemical, or biological properties that are associated with or affect safety and efficacy of therapy products. the set of chemical modifications to DNA and DNA-associated proteins, which regulate gene expression without modification of the DNA sequence. These modifications are heritable to daughter cells after cell division. the noncellular material external to cells, composed of structural and soluble molecules that can provide a rich biochemical and biomechanical signaling environment to cells. multiprotein clusters containing integrins that act as links between the ECM and the cellular cytoskeleton, relaying mechanical forces and signaling to the cell. controlled modification of DNA sequences through the use of engineered nucleases to induce double-stranded breaks in DNA. Zinc finger nucleases, Tal-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeats (CRISPR) technology are popular methods of editing genes within human cells. specifications of cell-based therapies to confirm the desired characteristics. a self-assembling 3D structure generated from stem cells, containing organ-specific cell types that may incorporate some features of the represented organ. existence and effectiveness of the desired biological functionality. lack of undesired components (contaminants) in the final product. modifying the epigenomic state of cells to change their identity. cells that can self-renew and differentiate into multiple different cell types. Pluripotent stem cells can differentiate into any cell type in the adult organism, and iPSCs can be generated through reprogramming somatic cells. Adult stem cells are present in multiple organs and are more restricted in the range of cell types they can differentiate into. They can be found in bone marrow (hematopoietic and mesenchymal stem cells), the brain (neural stem cells), and several other organs." @default.
• W2734672213 created "2017-07-21" @default.
• W2734672213 creator A5072591144 @default.
• W2734672213 creator A5087358894 @default.
• W2734672213 date "2017-10-01" @default.
• W2734672213 modified "2023-10-03" @default.
• W2734672213 title "Manufacturing Cell Therapies Using Engineered Biomaterials" @default.
• W2734672213 cites W1102314079 @default.
• W2734672213 cites W1511729762 @default.
• W2734672213 cites W1587848884 @default.
• W2734672213 cites W1600024584 @default.
• W2734672213 cites W1695434601 @default.
• W2734672213 cites W1819927554 @default.
• W2734672213 cites W1839053269 @default.
• W2734672213 cites W1847168200 @default.
• W2734672213 cites W1945220000 @default.
• W2734672213 cites W1967188390 @default.
• W2734672213 cites W1968952650 @default.
• W2734672213 cites W1970368333 @default.
• W2734672213 cites W1974773432 @default.
• W2734672213 cites W1982323513 @default.
• W2734672213 cites W1985213590 @default.
• W2734672213 cites W1986595047 @default.
• W2734672213 cites W1991037959 @default.
• W2734672213 cites W1997246078 @default.
• W2734672213 cites W1997304392 @default.
• W2734672213 cites W2000880710 @default.
• W2734672213 cites W2003315801 @default.
• W2734672213 cites W2010201046 @default.
• W2734672213 cites W2010723976 @default.
• W2734672213 cites W2016956692 @default.
• W2734672213 cites W2018258390 @default.
• W2734672213 cites W2020197664 @default.
• W2734672213 cites W2021774330 @default.
• W2734672213 cites W2023375384 @default.
• W2734672213 cites W2030338665 @default.
• W2734672213 cites W2045295282 @default.
• W2734672213 cites W2047649125 @default.
• W2734672213 cites W2050847381 @default.
• W2734672213 cites W2052159842 @default.
• W2734672213 cites W2054790573 @default.
• W2734672213 cites W2057451703 @default.
• W2734672213 cites W2057781728 @default.
• W2734672213 cites W2057917964 @default.
• W2734672213 cites W2058500387 @default.
• W2734672213 cites W2058720965 @default.
• W2734672213 cites W2059378220 @default.
• W2734672213 cites W2061224397 @default.
• W2734672213 cites W2074127181 @default.
• W2734672213 cites W2081958397 @default.
• W2734672213 cites W2089917293 @default.
• W2734672213 cites W2093458639 @default.
• W2734672213 cites W2100454719 @default.
• W2734672213 cites W2103095259 @default.
• W2734672213 cites W2106647511 @default.
• W2734672213 cites W2109173007 @default.
• W2734672213 cites W2109177948 @default.
• W2734672213 cites W2112424756 @default.
• W2734672213 cites W2123771262 @default.
• W2734672213 cites W2127033802 @default.
• W2734672213 cites W2130568296 @default.
• W2734672213 cites W2130814631 @default.
• W2734672213 cites W2134208433 @default.
• W2734672213 cites W2146606376 @default.
• W2734672213 cites W2148828403 @default.
• W2734672213 cites W2149083161 @default.
• W2734672213 cites W2149884610 @default.
• W2734672213 cites W2152392358 @default.
• W2734672213 cites W2159999899 @default.
• W2734672213 cites W2163149880 @default.
• W2734672213 cites W2163404991 @default.
• W2734672213 cites W2171253547 @default.
• W2734672213 cites W2172957891 @default.
• W2734672213 cites W2182456467 @default.
• W2734672213 cites W2183389629 @default.
• W2734672213 cites W2193321641 @default.
• W2734672213 cites W2202882799 @default.
• W2734672213 cites W2208179253 @default.
• W2734672213 cites W2221267861 @default.
• W2734672213 cites W2228561711 @default.
• W2734672213 cites W2233240510 @default.
• W2734672213 cites W2236943266 @default.
• W2734672213 cites W2256191215 @default.
• W2734672213 cites W2272541547 @default.
• W2734672213 cites W2278743348 @default.
• W2734672213 cites W2290372091 @default.
• W2734672213 cites W2295769945 @default.
• W2734672213 cites W2300048866 @default.
• W2734672213 cites W2312446230 @default.
• W2734672213 cites W2333997296 @default.
• W2734672213 cites W2334679613 @default.
• W2734672213 cites W2337841870 @default.
• W2734672213 cites W2341798131 @default.
• W2734672213 cites W2345730768 @default.
• W2734672213 cites W2347191528 @default.
• W2734672213 cites W2461407658 @default.
• W2734672213 cites W2508292514 @default.
• W2734672213 cites W2515679023 @default.

• next